Bioengineering

Gemin X Pharmaceuticals, Inc. Appoints Eric Roberts to Board of Directors

Published in Healthcare Finance, Tax and Law Weekly, October 17th, 2007

Gemin X Pharmaceuticals, Inc., a privately-held biopharmaceutical company focused on developing novel treatments for cancer, is pleased to announce the appointment of Eric W. Roberts to its Board of Directors.

Mr. Roberts is currently Managing Director of Caxton Advantage. >From 2000 to 2003, he was Managing Director and Co-Head of the Global Healthcare Investment Banking Group at Lehman Brothers and was previously Head of Life Sciences Investment Banking at UBS and Dillon, Read & Co. Inc. Mr. Roberts is a co-founder of Caxton Advantage, along with A. Rachel Leheny, the former Senior Biotechnology Analyst at Lehman Brothers, UBS and Hambrecht & Quist.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly

Source: Healthcare Finance, Tax and Law Weekly (2007-10-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry